Amicus TherapeuticsFOLD
About: Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
Employees: 517
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
132% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 25
20% more funds holding in top 10
Funds holding in top 10: 5 [Q2] → 6 (+1) [Q3]
12% more funds holding
Funds holding: 255 [Q2] → 286 (+31) [Q3]
3% more capital invested
Capital invested by funds: $3.32B [Q2] → $3.41B (+$92.8M) [Q3]
2% less repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 91
5.26% less ownership
Funds ownership: 113.06% [Q2] → 107.8% (-5.26%) [Q3]
29% less call options, than puts
Call options by funds: $6.37M | Put options by funds: $8.9M
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
Cantor Fitzgerald Kristen Kluska 39% 1-year accuracy 42 / 108 met price target | 116%upside $21 | Overweight Reiterated | 15 Jan 2025 |
Morgan Stanley Jeffrey Hung 47% 1-year accuracy 8 / 17 met price target | 24%upside $12 | Equal-Weight Downgraded | 13 Dec 2024 |
JP Morgan Anupam Rama 31% 1-year accuracy 18 / 59 met price target | 75%upside $17 | Overweight Maintained | 12 Nov 2024 |
Guggenheim Debjit Chattopadhyay 40% 1-year accuracy 8 / 20 met price target | 55%upside $15 | Buy Maintained | 7 Nov 2024 |
UBS Karl Chalabala 50% 1-year accuracy 1 / 2 met price target | 116%upside $21 | Buy Maintained | 7 Nov 2024 |
Financial journalist opinion
Based on 6 articles about FOLD published over the past 30 days
